Drug company Tiofarma has admitted that it took part in an agreement that resulted in significant price hikes for an essential medicine, reported the Competition and Markets Authority (CMA).
This means that 2 of the 3 companies under investigation by the CMA have now admitted to an allegation that they illegally took part in an anti-competitive agreement.
The CMA has alleged, and provisionally found, that the agreement between Aspen, Tiofarma, and Amilco contributed to the price of fludrocortisone acetate tablets supplied to the NHS increasing by up to 1800%. Fludrocortisone is a life-saving medicine that thousands of patients rely on to treat adrenal insufficiency, commonly known as Addison’s Disease.
In October 2019, the CMA issued a “statement of objections” provisionally finding that the 3 suppliers had broken the law. The CMA’s provisional finding was that the agreement involved Tiofarma and Amilco staying out of the UK fludrocortisone market so that Aspen could maintain its position as the sole UK supplier. The CMA also provisionally found that, in exchange, Tiofarma was given the right to be the sole manufacturer of the drug for direct sale in the UK, and Amilco received a 30% share of the increased prices that Aspen was able to charge.
Featured News
Antitrust Lawsuit Targets RTX’s Pratt & Whitney Canada
May 14, 2024 by
CPI
Former Sales Pro Admits to Bid Rigging Targeting US Schools
May 13, 2024 by
CPI
Macron Advocates EU Financial Integration Amid Push for Global Competitiveness
May 13, 2024 by
CPI
Microsoft Faces EU Antitrust Charges Over Teams Software
May 13, 2024 by
CPI
EU Antitrust Complaint Filed Against Edwards Lifesciences by Indian Rival Meril
May 13, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI